and committee democrat diana degette of colorado complained republicans had been irresponsible in handling e- mails. >> i am just as much concerned about this solyndra loan as everybody else is, but the way that the information has been parceled out. the witness don't have the full copies in front of them, the minority doesn't have the full copy in front of them until we ask for them, that is not in the grand tradition of this subcommittee. >> suarez: two of solyndra's top executives did not testify today. another hearing is planned next week, and they are expected to speak then. carol leonig has been reporting on this story for the "washington post" and watched the hearing today. she joins us now. we saw those exchanges on capitol hill today. did they help fill in any part of this story? did we learn anything new about the life cycle of solyndra? >> not a terrible lot was learned about the life cycle of solyndra but you heard a more full-throated explanation from the department of energy and the office of management and budget inside the obama administration, why they believe the... you k

colorado congresswoman diana degette recently introduced a bill requiring drugmakers to notify the fdaf possible shortages. this energy and commerce subcommittee hearing is just under three hours. >> the subcommittee will come to order. the chair recognizes himself for five minutes for an opening statement. in a 2005, 61 drug shortages were reported to the fda. by 2010, there were 178 reported drug shortages. 132 of which involved sterile injectable drugs. so far, this year fda has continued to see an increasing number of shortages, especially those involving older sterile injected drugs. these shortages have involved cancer drugs, anesthetics used for patients undergoing surgery as well as drugs need for emergency medicine and e electrolytes need for patience on of ev feeding. it appears that there are many potential causes for the drug shortages. in some cases shortages have been caused by quality and manufacturing issues. additionally production delays at the manufactured level including limited production lines for certain older drugs and difficulty in receiving of rall materials a

my colleague representative diana degette has introduced bipartisan legislation h.r. 2245, the prserving access to life-saving medications act of 2011, as a first step in addressing this issue. this legislation would require manufacturers to notify the fda of any actual or perspective drug shortages, and i want to commend representative degette on pioneering this effort and hope that as a result of hearing from the witnesses today, we can identify additional solutions to this growing problem. this hearing will allow us to learn more about why drug shortages are occurring, with the administration and industry are doing to address the problem and what new authorities the fda might need to do to prevent shortages from happening in he future. and i am encouraged that we are exploring this issue in the subcommittee today and look forward to working with you, chairman, as we get to the bottom of this issue and again, thank you for having me here and i yield back. >> the chair recognizes the ranking member of the full committee,r. waxman for five minutes. >> thank you, chairman pets for recogni

. >> reporter: ranking democrat diana degette says that the taxpayers have a right to know what happened to half a billion dollars, but she says that the solyndra case should not be used as an excuse not to fund other clean energy projects. and the committee said they were badgering the witnesses, so when they found out that it was clear they would not be answering the questions, she said that they were using cheap gimmicks not to answer the questions. >> so they looked stony and as you asked them the question, they kept on walking, is that right? >> yes, we asked questions to both the cfo as he was walking out as well as to the ceo brian harrison and we didn't get any kind of comment. we also addressed questions to their attorneys and their attorneys did not even make a statement at all, nothing of any sort, and not even a no comment. nothing from them. >> it is one thing for the principles not to comment, but another for the attorneys not the comment. thank you, lisa. good work. >>> searching for the cause after a deadly air show crash, and what investigators are hoping to learn from m

host: democrats on the committee, henry waxman and diana degette, have sent two letters to the oversight committee of energy and commerce, first of all, they want the committee to have those that invested, private investors to the tune of about $1 billion each to come before the committee and testify as to why they gave money to solyndra. perhaps there's evidence they can provide that they thought this was a viable corporation, a viable company and that's why they went forward with their money. guest: it's worth asking those questions. but the other issue, if that was the case, they thought it was viable, why and who pushed for the switch of the taxpayers number two and the investors are number one. mr. kaiser put together many of these loans. the series this year was $75 million, the government put in $70 million of taxpayers' money. but we need details of the timeline, who knew what, when. that may be a valid question. host: and they wrote a letter to congressman cliff stearns saying that the chief executive officer of solyndra met with us to assure us they were in a strong financial p

[applause] congresswoman diana degette, congressman ed perlmutter.[cheers and applause] you're own home town mayor michael hancock. [cheers and applause] and former friend -- current friend, former mayor -- [laughter] -- and one of the finest public servants in colorado history. [cheers and applause] so it is good to be back in colorado, especially on a gorgeous day like this. [cheers and applause] it's always like this in late september, isn't it? absolutely. it is an honor to be here at lincoln high school. [cheers and applause] and i want to get a special thank you to a million for that wonderful introduction. [cheers and applause] i was just talking to emelia, she is a senior this year and she is planning to go to college and planning to be a doctor, and i'm absolutely certain she is going to succeed in everything that she does. and she's an example, a great example of how smarter courses and better technology can help guarantee our kids the foundation that they need to graduate and compete in this new global economy. so, we couldn't be prouder o

with that i recognize the ranking member diana degette. >> thank you very much mr. chairman for convening this hearing. i think oversight directed towards ensuring efficient and effective federal regulation is an important endeavor and i'd like to work with a majority to have efforts to root out unnecessary and wasteful regulations. as a long-time member of this distinguished subcommittee i believe the purpose of this committee is to investigate what can be done, not to forward the political agenda so i know we are going to have a heated discussion today but i think we should keep it focused on exactly what regulations we are talking about, what but the purposes and in fact if they are necessary. to that end, i'm delighted to welcome our witness today. it epa administrator lisa jackson. administrator jackson oversees implementation of some of the most important legislation ever passed by congress and it is my view she is one of the most gutsy and effective members of the administration, so i'm glad to have her. the main topic of the conversation today will be jobs.

with that i recognize the distinguished ranking member, diana degette from colorado. >> thank you very much, mr. chairman, for conving this hearing. i think that oversight directed towards efficient and effective endeavor is an important en defer. we need to root out wasteful regulations. as a one-time member of the distinguished subcommittee, i believe the purpose of this committee is to investigate what can be done, not to forward a political agenda. and so i know we're going to have a heated discussion today, but i think we should keep it focused on exactly what regulations we're talking about, what the purpose is and if in fact they're necessary. to that end, i'm delighted to welcome our witness today, e.p.a. administer lisa jackson. administrator jackson oversees implementation of some of the most important legislation ever passed by congress and its my view that she's one of the most gutsy and effective members of the administration. the main topic of the conversation today will be jobs. i know that my colleagues on the other side of the aisle will assert that environmental rules

my colleague representative diana degette has introduced bipartisan legislation h.r. 2245, the preserving access to life-saving medications act of 2011, as a first step in addressing this issue. this legislation would require manufacturers to notify the fda of any actual or perspective drug shortages, and i want to commend representative degette on pioneering this effort and hope that as a result of hearing from the witnesses today, we can identify additional solutions to this growing problem. this hearing will allow us to learn more about why drug shortages are occurring, with the administration and industry are doing to address the problem and what new authorities the fda might need to do to prevent shortages from happening in the future. and i am encouraged that we are exploring this issue in the subcommittee today and look forward to working with you, chairman, as we get to the bottom of this issue and again, thank you for having me here and i yield back. >> the chair recognizes the ranking member of the full committee, mr. waxman for five minutes. >> thank you, chairman pets for reco